CUE vs RUN · rev $9.3M vs P/E 6.0, rev $2.04B
Cue Biopharma (CUE) versus Sunrun Inc (RUN) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
CUE currently screens at market cap $59.5M. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Not investment advice. Open the CUE and RUN stock pages for the full models.
Not investment advice.